Splunk (NASDAQ:SPLK) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(0.35) by 271.43 percent. This is a 109.68 percent decrease over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $799.00 million which beat the analyst consensus estimate of $747.55 million by 6.88 percent. This is a 31.90 percent increase over sales of $605.74 million the same period last year.
FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron’s COVID-19 Antibody Cocktail
The FDA has authorized a new, lower-dose version of Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) COVID-19 monoclonal antibody cocktail for those with COVID-19 who…
